File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Are oxidative stress markers useful to predict clinical progression in Parkinson’s disease? A case-control study

TitleAre oxidative stress markers useful to predict clinical progression in Parkinson’s disease? A case-control study
Authors
Issue Date2009
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/76507419
Citation
The 13th Movement Disorder Society (MDS) International Congress of Parkinson's Disease and Movement Disorders, Paris, France, 7-11 June 2009. In Movement Disorders, 2009, v. 24 n. Suppl. 1, p. S46-S47, abstract no. Th-17 How to Cite?
AbstractObjective: To compare the levels of lipid peroxidation products between Parkinson’s disease (PD) and study controls, and the relationship of these products in relation to clinical progression in PD. Background: Oxidative stress may be important in the pathogenesis of Parkinson’s disease (PD). The extent of oxidative stress damage was assessed using markers of lipid peroxidation in a cohort of PD patients and study controls. Methods: A total of 62 PD patients and 86 age-gender matched study controls (25 ischemic stroke and 61 community-based healthy controls) participated in this study. Their demographic and clinical characteristics were obtained using a standardized questionnaire. In PD patients, the clinical severity of their disease was assessed using the Hoehn-Yahr scale and the Unified Parkinson’s Disease Rating scales (UPDRS), and their cumulative exposure to levodopa calculated. Markers of lipid peroxidation (F2-isoprostanes, F2-IsoPs; hydroxyeicosatetraenoic acid, HETEs; and cholesterol oxidation products, COPs), were assessed in the plasma and urine samples using the gas chromatography-mass spectrometry method. Results: The mean (standard deviation) age was 64 (8) years and there were no differences in the gender, ethnicity and medical history in the PD and study control groups (p>0.05). Higher levels of plasma esterified F2-IsoPs, plasma free HETEs and COPs were observed in PD patients as compared to stroke and healthy controls (p<0.05, t-test). No significant correlation was observed between F2- IsoPs, HETEs and COPs in relation to the cumulative dosage of levodopa (r5 -0.15 to 0.21). A significant decrease in plasma free F2-IsoPs was observed with clinical progression of PD, according to the Hoehn-Yahr (p-trend<0.05) and UPDRS severity scales (r5 -0.372, p50.004). After adjusting for age, gender and cumulative levodopa dosage, lower plasma levels of free F2-IsoPs independently predicted UPDRS scores (OR -292, 95% CI -527 to -56). Conclusions: We identified certain markers of lipid peroxidation and COPs to be elevated in PD and suggested the use of plasma free F2-IsoPs as a potential marker of clinical progression.
Persistent Identifierhttp://hdl.handle.net/10722/185201
ISSN
2015 Impact Factor: 6.01
2015 SCImago Journal Rankings: 2.733

 

DC FieldValueLanguage
dc.contributor.authorSeet, RCSen_US
dc.contributor.authorLee, JCYen_US
dc.contributor.authorLim, ECHen_US
dc.contributor.authorTan, JJH-
dc.contributor.authorQuek, AML-
dc.contributor.authorChong, WL-
dc.contributor.authorLooi, WF-
dc.contributor.authorHuang, H-
dc.contributor.authorHuang, SH-
dc.contributor.authorHalliwell, B-
dc.date.accessioned2013-07-15T10:41:27Z-
dc.date.available2013-07-15T10:41:27Z-
dc.date.issued2009en_US
dc.identifier.citationThe 13th Movement Disorder Society (MDS) International Congress of Parkinson's Disease and Movement Disorders, Paris, France, 7-11 June 2009. In Movement Disorders, 2009, v. 24 n. Suppl. 1, p. S46-S47, abstract no. Th-17en_US
dc.identifier.issn0885-3185en_US
dc.identifier.urihttp://hdl.handle.net/10722/185201-
dc.description.abstractObjective: To compare the levels of lipid peroxidation products between Parkinson’s disease (PD) and study controls, and the relationship of these products in relation to clinical progression in PD. Background: Oxidative stress may be important in the pathogenesis of Parkinson’s disease (PD). The extent of oxidative stress damage was assessed using markers of lipid peroxidation in a cohort of PD patients and study controls. Methods: A total of 62 PD patients and 86 age-gender matched study controls (25 ischemic stroke and 61 community-based healthy controls) participated in this study. Their demographic and clinical characteristics were obtained using a standardized questionnaire. In PD patients, the clinical severity of their disease was assessed using the Hoehn-Yahr scale and the Unified Parkinson’s Disease Rating scales (UPDRS), and their cumulative exposure to levodopa calculated. Markers of lipid peroxidation (F2-isoprostanes, F2-IsoPs; hydroxyeicosatetraenoic acid, HETEs; and cholesterol oxidation products, COPs), were assessed in the plasma and urine samples using the gas chromatography-mass spectrometry method. Results: The mean (standard deviation) age was 64 (8) years and there were no differences in the gender, ethnicity and medical history in the PD and study control groups (p>0.05). Higher levels of plasma esterified F2-IsoPs, plasma free HETEs and COPs were observed in PD patients as compared to stroke and healthy controls (p<0.05, t-test). No significant correlation was observed between F2- IsoPs, HETEs and COPs in relation to the cumulative dosage of levodopa (r5 -0.15 to 0.21). A significant decrease in plasma free F2-IsoPs was observed with clinical progression of PD, according to the Hoehn-Yahr (p-trend<0.05) and UPDRS severity scales (r5 -0.372, p50.004). After adjusting for age, gender and cumulative levodopa dosage, lower plasma levels of free F2-IsoPs independently predicted UPDRS scores (OR -292, 95% CI -527 to -56). Conclusions: We identified certain markers of lipid peroxidation and COPs to be elevated in PD and suggested the use of plasma free F2-IsoPs as a potential marker of clinical progression.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/76507419en_US
dc.relation.ispartofMovement Disordersen_US
dc.rightsMovement Disorders. Copyright © John Wiley & Sons, Inc.en_US
dc.titleAre oxidative stress markers useful to predict clinical progression in Parkinson’s disease? A case-control studyen_US
dc.typeConference_Paperen_US
dc.identifier.emailLee, JCY: jettylee@hku.hken_US
dc.identifier.authorityLee, JCY=rp01511en_US
dc.identifier.doi10.1002/mds.22628-
dc.identifier.hkuros214520en_US
dc.identifier.volume24en_US
dc.identifier.issueSuppl. 1-
dc.identifier.spageS46, abstract no. Th-17en_US
dc.identifier.epageS47, abstract no. Th-17en_US
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats